 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...89101112131415161718...99100» |
- | letrozole / Generic mfg.
Enrollment change, Trial withdrawal: Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. (clinicaltrials.gov) - Feb 20, 2024
P4, N=0, Withdrawn, Sponsor: Dubai Fertility Center
N=236 --> 0 | Not yet recruiting --> Withdrawn
- | denifanstat (TVB-2640) / Sagimet Biosci
Enrollment closed, Enrollment change: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 18, 2024
P2, N=19, Active, not recruiting, Sponsor: Mayo Clinic
N=236 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=80 --> 19
- Pathologic Features and Residual Cancer Burden (RCB) after Neoadjuvant Endocrine Therapy (NET) in Hormone Receptor Positive Breast Cancer (HR+ BC) (Exhibit Hall; Poster Board Number: 34) - Feb 18, 2024 - Abstract #USCAP2024USCAP_2205;
NET before surgery induces similar pathologic changes in the tumor bed as NACT. Many pathologists do not report post NET specimens as they report post NACT specimens due to lack of awareness and clear guidelines.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method. (Pubmed Central) - Feb 17, 2024
A simple and robust LC-MS/MS method was successfully validated for the simultaneous quantification of CDK4/6is, M2, M20, and letrozole in human plasma. The assay was found to be suitable for measuring steady-state trough concentrations of the analytes in patient samples.
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P3, N=3100, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
The assay was found to be suitable for measuring steady-state trough concentrations of the analytes in patient samples. Trial primary completion date: Jul 2028 --> Sep 2029
- |||| Ibrance (palbociclib) / Pfizer
Trial primary completion date: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P3, N=496, Active, not recruiting, Sponsor: Alliance Foundation Trials, LLC.
Trial primary completion date: Jul 2028 --> Sep 2029 Trial primary completion date: Dec 2023 --> Apr 2024
- | letrozole / Generic mfg.
Phase classification: LETRODON: Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors. (clinicaltrials.gov) - Feb 15, 2024
P3, N=152, Active, not recruiting, Sponsor: IVI Madrid
Trial primary completion date: Dec 2023 --> Apr 2024 Phase classification: P4 --> P3
- || amcenestrant (SAR439859) / Sanofi
Trial completion date, Monotherapy, Metastases: AMEERA-3: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=367, Active, not recruiting, Sponsor: Sanofi
Phase classification: P4 --> P3 Trial completion date: Dec 2023 --> Mar 2024
- | Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=40, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2023 --> Mar 2024 Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- | letrozole / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial (clinicaltrials.gov) - Feb 15, 2024
P4, N=8, Terminated, Sponsor: Rigshospitalet, Denmark
Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 N=60 --> 8 | Trial completion date: Dec 2023 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Aug 2023; Lack of recruitment
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
New trial, Metastases: A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=34, Recruiting, Sponsor: Second Affiliated Hospital of Soochow University
- | letrozole / Generic mfg.
New P3 trial, New P4 trial: LETRODON: Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors. (clinicaltrials.gov) - Feb 15, 2024
P4, N=152, Active, not recruiting, Sponsor: IVI Madrid
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P2 trial: Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors (clinicaltrials.gov) - Feb 15, 2024
P2, N=30, Recruiting, Sponsor: Fengzhi Feng
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Journal: Development of an App for Symptom Management in Women With Breast Cancer Receiving Maintenance Aromatase Inhibitors: Protocol for a Mixed Methods Feasibility Study. (Pubmed Central) - Feb 15, 2024
P=N/A
N=60 --> 8 | Trial completion date: Dec 2023 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Aug 2023; Lack of recruitment This protocol describes a study investigating the feasibility, acceptability, and usability of the symptom management tool Bone@BC developed for patients with breast cancer with an endocrine aspect.
- ||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion, Metastases: BioItaLEE: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (clinicaltrials.gov) - Feb 13, 2024
P3, N=287, Completed, Sponsor: Novartis Pharmaceuticals
This protocol describes a study investigating the feasibility, acceptability, and usability of the symptom management tool Bone@BC developed for patients with breast cancer with an endocrine aspect. Active, not recruiting --> Completed
- | letrozole / Generic mfg.
Journal: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study. (Pubmed Central) - Feb 12, 2024
P4
The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies.
- ||| BGB-43395 / BeiGene
New P1 trial, Combination therapy, Metastases: BGB-43395-102: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (clinicaltrials.gov) - Feb 12, 2024
P1, N=78, Not yet recruiting, Sponsor: BeiGene
- | letrozole / Generic mfg.
Preclinical, Journal: Effect of Aromatase Inhibitor Letrozole on the Placenta of Adult Albino Rats: A Histopathological, Immunohistochemical, and Biochemical Study. (Pubmed Central) - Feb 11, 2024
It interrupted stimulatory vascular signals causing significant apoptosis and placental vascular dysfunction. Letrozole in an equivalent human daily dose of 10 mg caused a high post-implantation loss rate without imposing severe side effects.
- | letrozole / Generic mfg., fulvestrant / Generic mfg., flutamide / Generic mfg.
Preclinical, Journal: Development of Porcine Accessory Sex Glands. (Pubmed Central) - Feb 10, 2024
The presence of both classical nuclear estrogen receptors and the G protein-coupled estrogen receptor in neonatal accessory sex glands indicated multiple signaling pathways might mediate the growth inhibition by endogenous estrogens. The absence of a detectable response when the classical estrogen receptors were blocked with fulvestrant (or when the androgen receptor was blocked with flutamide) suggests that endogenous estrogens act through the G protein-coupled estrogen receptor to inhibit the development of accessory sex glands during this neonatal to early juvenile interval.
- | progesterone / Generic mfg., letrozole / Generic mfg.
Journal: Natural Cycle Frozen Embryo Transfer: Evaluating Optimal Protocols for Preparation and Timing. (Pubmed Central) - Feb 7, 2024
In NC-FET, a variety of preparation and timing protocols may lead to comparable cycle outcomes, potentially allowing for flexibility on the basis of patient and physician preference. These findings warrant validation in a larger, randomised trial.
- | letrozole / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: IUI With Letrozole Versus in Natural Cycle (clinicaltrials.gov) - Feb 7, 2024
P=N/A, N=982, Recruiting, Sponsor: Peking University Third Hospital
These findings warrant validation in a larger, randomised trial. Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- | letrozole / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients (clinicaltrials.gov) - Feb 7, 2024
P=N/A, N=200, Completed, Sponsor: Capital Medical University
Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Dec 2025 Unknown status --> Completed
- | Verzenio (abemaciclib) / Eli Lilly
Journal: Recurrent Breast Cancer with Bone Metastasis Effectively Treated with Abemaciclib plus Endocrine Therapy-A Case Report (Pubmed Central) - Feb 6, 2024
The elevated tumor markers normalized and have continued to decrease. Abemaciclib combined with endocrine therapy was significantly effective as first-line treatment for premenopausal women with metastatic breast cancer.
- | lapatinib / Generic mfg., letrozole / Generic mfg., fulvestrant / Generic mfg.
Journal, Metastases: Elderly Advanced Breast Cancer Effectively Treated with Locoregional Therapy-A Case Report (Pubmed Central) - Feb 6, 2024
By changing the endocrine therapy to toremifene followed by fulvestrant, the therapy achieved a partial response...She was administered lapatinib as anti-HER2 therapy in addition to the endocrine therapy. Two years and 6 months after surgery, there has been no worsening of bone metastasis or appearance of visceral metastasis.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Application of double-layer soft tissue suture closure technique in the surgical treatment of patients with mandible medication-related osteonecrosis of the jaw of early and medium stages (Pubmed Central) - Feb 6, 2024
Two years and 6 months after surgery, there has been no worsening of bone metastasis or appearance of visceral metastasis. The double-layer soft tissue suture closure technique can achieve good clinical results in patients with MRONJ of the mandible using anti-bone-resorptive drugs alone, and can provide clinical treatment ideas for MRONJ patients with more complicated drug use.
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Preclinical, Journal: Duguetia confinis Engl. & Diels (Annonaceae) inhibitory and cytotoxic effects on breast adenocarcinoma growth both in vitro and in vivo. (Pubmed Central) - Feb 6, 2024
The double-layer soft tissue suture closure technique can achieve good clinical results in patients with MRONJ of the mandible using anti-bone-resorptive drugs alone, and can provide clinical treatment ideas for MRONJ patients with more complicated drug use. The in vivo study consisted in a once-off administration of 50
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Feb 6, 2024
P2, N=377, Active, not recruiting, Sponsor: MedSIR
The in vivo study consisted in a once-off administration of 50 Completed --> Active, not recruiting | Trial completion date: Nov 2023 --> Nov 2026
- | letrozole / Generic mfg.
Preclinical, Journal: Aromatase inhibitors identified from Saraca asoca to treat infertility in women with polycystic ovary syndrome via in silico and in (Pubmed Central) - Feb 5, 2024
Completed --> Active, not recruiting | Trial completion date: Nov 2023 --> Nov 2026 Of the 10, procyanidin B2 and luteolin showed better interaction with higher binding energy when docked against aromatase (3S79) as compared to the commercial inhibitor letrozole...A dose-dependent administration of these two compounds on zebrafish revealed that both the compounds, at a lower concentration of 50?
- ||| Kisqali (ribociclib) / Novartis
P3 data, Journal, Combination therapy, Metastases: Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. (Pubmed Central) - Feb 5, 2024
Of the 10, procyanidin B2 and luteolin showed better interaction with higher binding energy when docked against aromatase (3S79) as compared to the commercial inhibitor letrozole...A dose-dependent administration of these two compounds on zebrafish revealed that both the compounds, at a lower concentration of 50? In this broad population of patients with HR+HER2- ABC, efficacy and safety results of ribociclib plus letrozole were similar to those observed in pivotal trials.
- Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multi-Center Study () - Feb 3, 2024 - Abstract #SGO2024SGO_605;
- | letrozole / Generic mfg.
Journal: Sequential 2.5 mg letrozole/FSH therapy is more effective for promoting pregnancy in infertile women with PCOS: a pragmatic randomized controlled trial. (Pubmed Central) - Feb 2, 2024
The data indicate that the sequential letrozole 2.5mg/FSH protocol may be more effective than the sequential letrozole 5mg/FSH protocol for promoting pregnancy in infertile women with PCOS. www.chictr.org.cn, identifier ChiCTR2300069638.
- | letrozole / Generic mfg., megestrol / Generic mfg.
Trial completion, Trial completion date: PIONEER: A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer (clinicaltrials.gov) - Jan 30, 2024
P2, N=198, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
www.chictr.org.cn, identifier ChiCTR2300069638. Recruiting --> Completed | Trial completion date: Nov 2022 --> Oct 2023
- | metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Preclinical, Journal: Allium ampeloprasum var. Porrum (Alliaceae) Improves Metabolic and Reproductive Disorders Associated with Polycystic Ovary Syndrome in Wistar Rats. (Pubmed Central) - Jan 29, 2024
To provide scientific evidence of the efficacy of Allium ampeloprasum against female infertility, the effects of the aqueous extract of the said plant (AE) were evaluated in rats with letrozole-induced polycystic ovary syndrome (PCOS)...The positive control was co-treated with clomiphene citrate (1?mg/kg) and metformin (200?mg/kg)...These effects were attributed to phenols, flavonoids, terpenoids, and anthocyanins present in AE. The overall results justify the traditional use of A. ampeloprasum against female infertility and suggest its potential use as a dietary supplement for PCOS patients.
- | Verzenio (abemaciclib) / Eli Lilly
Journal: Bone Marrow Carcinomatosis with Disseminated Intravascular Coagulation in a Breast Cancer Patient Treated with Chemotherapy and CDK4/6 Inhibitor (Pubmed Central) - Jan 26, 2024
Therefore, a diagnosis of bone marrow carcinomatosis and disseminated intravascular coagulation was made. Treatment was started with chemotherapy(epirubicin and cyclophosphamide)and subsequently changed to an aromatase inhibitor(letrozole)and a CDK4/4 inhibitor(abemaciclib) and was maintained without exacerbation of the patient's condition.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
ONE BATTLE AFTER ANOTHER: BEVACIZUMAB CARDIOMYOPATHY AFTER HIGH-GRADE ENDOMETRIAL CARCINOMA (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4920;
Around 2-4% of bevacizumab-treated patients develop cardiomyopathy and heart failure. Bevacizumab biosimilar cardiotoxicity data are limited.
- lisinopril / Generic mfg.
ACUTE PANCREATITIS SECONDARY TO LISINOPRIL USE (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_1309;
The etiology of cardiomyopathy was suspected to be due to letrozole use for treatment of primary breast cancer. Physicians, both as prescribers and as providers of acute care, should be aware of pancreatitis as an uncommon side effect of ACE-inhibitors so that the offending agent can be promptly discontinued and the true prevalence of this condition can be determined.
- | maveropepimut-S (MVP-S) / BioVaxys
Trial primary completion date: Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer (clinicaltrials.gov) - Jan 25, 2024
P1, N=6, Active, not recruiting, Sponsor: Providence Health & Services
Physicians, both as prescribers and as providers of acute care, should be aware of pancreatitis as an uncommon side effect of ACE-inhibitors so that the offending agent can be promptly discontinued and the true prevalence of this condition can be determined. Trial primary completion date: Nov 2023 --> Jun 2023
- | New P3 trial: SWE-Switch: Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer (clinicaltrials.gov) - Jan 25, 2024
P3, N=3832, Not yet recruiting, Sponsor: Region
- |||||| Orserdu (elacestrant) / Menarini
Enrollment open: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (clinicaltrials.gov) - Jan 24, 2024
P3, N=220, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Nov 2023 --> Jun 2023 Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: NCI-2021-12428: Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - Jan 23, 2024
P4, N=60, Suspended, Sponsor: University of Washington
Not yet recruiting --> Recruiting Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Hiltonol (poly-ICLC) / Oncovir
New P1 trial: Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (clinicaltrials.gov) - Jan 23, 2024
P1, N=50, Not yet recruiting, Sponsor: Finn, Olivera, PhD
- | Enrollment change, Trial withdrawal: SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) - Jan 23, 2024
P1, N=0, Withdrawn, Sponsor: OHSU Knight Cancer Institute
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 N=25 --> 0 | Not yet recruiting --> Withdrawn
- | fulvestrant / Generic mfg.
Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution. (Pubmed Central) - Jan 22, 2024
Estimated effectiveness (OS) of letrozole and fulvestrant was, respectively, 3.2-3.5 months lower than reported. The clinical meaning seems uncertain and may be explained a higher proportion of worse prognostic characteristics in patients treated in the real-world.
- letrozole / Generic mfg.
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in earlystage breast cancer () - Jan 22, 2024 - Abstract #YIR2024YIR_110;
Letrozole also improved breast cancer-free interval and distant recurrences without improving overall survival. Careful assessment of potential risks and benefits is necessary for selecting appropriate candidates for ELT.
- Ibrance (palbociclib) / Pfizer
PARSIFAL-LONG: Extended follow-up of hormone receptor-positive HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study () - Jan 22, 2024 - Abstract #YIR2024YIR_35;
mPFS and mOS results are consistent with those reported in other first-line trials involving different CDK4/6i. Progression within the first year of first-line CDK4/6i-based regimen for HR+/HER2- ABC pts may be prognostic of less favorable outcomes.
- Kisqali (ribociclib) / Novartis
Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2? early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial () - Jan 22, 2024 - Abstract #YIR2024YIR_30;
Efficacy results confirm continued improvement in benefit across subgroups, including stage II disease. Safety findings support the manageable toxicity profile of RIB at the 400-mg starting dose in early breast cancer.
- Kisqali (ribociclib) / Novartis
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial () - Jan 22, 2024 - Abstract #YIR2024YIR_29;
P3
The NATALEE results support ribociclib + ET as the treatment of choice in a broad population of pts with stage II or III HR+/HER2? EBC, including pts with N0 disease
- Kisqali (ribociclib) / Novartis
Invasive disease-free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC) () - Jan 22, 2024 - Abstract #YIR2024YIR_28;
EBC were randomized 1:1 to RIB for 3 y (400 mg/d for 3 wk on/1 wk off ) + NSAI for ?5 y (letrozole 2.5 mg/d or anastrozole 1 mg/d) or NSAI alone. Premenopausal women and men received goserelin every 28 d. NATALEE included pts with anatomical stage IIA (N0 requiring additional risk factors or N1 [1-3 axillary lymph nodes]) and all pts with stage IIB or III disease per AJCC
- | Verzenio (abemaciclib) / Eli Lilly
Enrollment change, Metastases: AMBRE: Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (clinicaltrials.gov) - Jan 22, 2024
P3, N=180, Recruiting, Sponsor: UNICANCER
Premenopausal women and men received goserelin every 28 d. NATALEE included pts with anatomical stage IIA (N0 requiring additional risk factors or N1 [1-3 axillary lymph nodes]) and all pts with stage IIB or III disease per AJCC N=378 --> 180
- letrozole / Generic mfg.
Paraneoplastic Dermatomyositis : Case Report (Poster area) - Jan 18, 2024 - Abstract #ESGO2024ESGO_866;
She was treated with neoadjuvant chemotherapy followed by left Patey and letrozole hormonal therapy...She will have locoregional radiotherapy at a dose of 40 Gy and a BOOST of 13.35 Gy.Results Clinical outcomes showed no significant improvement and persistent pruritic dermatological lesions.Conclusion Paraneoplastic syndromes are a factor in both the diagnosis and monitoring of certain tumours. When dermatomyositis occurs in patients with a history of breast cancer, a relapse must be sought as a priority